Setting Ego Aside To Better Human Health
Interview With INOVIO's Kate Broderick
Executive Summary
Kate Broderick, SVP of research and development at INOVIO and one of In Vivo’s 2021 rising leaders, is hopeful that greater collaboration will be the lasting effect of COVID-19.
You may also be interested in...
Inovio Abandons Lassa, MERS Vaccines Shortly After Ending COVID-19 Booster Work
Two clinical-stage vaccine candidates for Lassa Fever and MERS, funded by CEPI, are being discontinued, but Inovio will continue its focus on DNA medicines for HPV-related conditions and cancer.
Ovid Therapeutics: Seeking Innovation In Epilepsy Treatment
Rising Leader Julia Tsai wants to see Ovid Therapeutics become a market leading epilepsy company that listens to the needs of patients and develops innovative drugs to treat a spectrum of epileptic indications and symptoms.
Synaffix’s Serial Dealmaker On ADC Platform Success And Expanding Into Gene Therapy
Anthony DeBoer, head of business development at Synaffix, joined the company in 2014 and has helped develop a platform technology business model in the antibody drug conjugate space, where Synaffix has become one of the leading technology providers enabling best-in-class therapeutic candidates.